SSTR5 ablation in islet results in alterations in glucose homeostasis in mice  by Wang, X.P. et al.
FEBS 29607 FEBS Letters 579 (2005) 3107–3114SSTR5 ablation in islet results in alterations in glucose homeostasis
in mice
X.P. Wanga,*, J. Yanga, M.A. Norman, J. Magnussona, F.J. DeMayob, F.C. Brunicardia
a Michael E. DeBakey Department of Surgery, Baylor College of Medicine, 402SA, One Baylor Plaza, Houston, TX 77030, USA
b Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
Received 6 April 2005; revised 25 April 2005; accepted 26 April 2005
Available online 11 May 2005
Edited by Robert BaroukiAbstract Somatostatin (SST) peptide is a potent inhibitor of
insulin secretion and its eﬀect is mediated via somatostatin recep-
tor 5 (SSTR5) in the endocrine pancreas. To investigate the conse-
quences of gene ablation of SSTR5 in themouse pancreas, we have
generated amousemodel inwhich the SSTR5genewas speciﬁcally
knocked down in the pancreatic beta cells (bSSTR5Kd) using the
Cre-lox system. Immunohistochemistry analysis showed that
SSTR5 gene expression was absent in beta cells at three months
of age.At the time of gene ablation, bSSTR5Kdmice demonstrated
glucose intolerance with lack of insulin response and signiﬁcantly
reduced serum insulin levels. Insulin tolerance test demonstrated a
signiﬁcant increase of insulin clearance in vivo at the same age. In
vitro studies demonstrated an absence of response to SST-28 stim-
ulation in the bSSTR5Kd mouse islet, which was associated with a
signiﬁcantly reduced SST expression level in bSSTR5Kdmice pan-
creata. In addition, bSSTR5Kd mice had signiﬁcantly reduced ser-
umglucose levels and increased serum insulin levels at 12months of
age. Glucose tolerance test at an older age also indicated a persis-
tently higher insulin level in bSSTR5Kd mice. Further studies of
bSSTR5Kd mice had revealed elevated serum C-peptide levels at
both 3 and 12months of age, suggesting that thesemice are capable
of producing and releasing insulin to the periphery. These results
support the hypothesis that SSTR5 plays a pivotal role in the reg-
ulation of insulin secretion in the mouse pancreas.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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knockout1. Introduction
Somatostatin (SST) peptide exists in two forms, SST-14 and
the N-terminally extended form, SST-28. SST-14 is the pri-
mary form found throughout the body with SST-28 secreted
from the gut mucosa [1]. SST is initially formed as a larger
preprosomatostatin molecule with 92 AA in mammals. This
peptide is cleaved at its C terminus to form SST-14 and SST-
28 [2–4]. Five SST receptors (SSTR1-5) have been isolated
and cloned from multiple mammalian species. They are lo-
cated on ﬁve diﬀerent chromosomes. SSTR1, 3, 4, and 5 genes
are intronless and code for a 400 AA protein [5–8]. SSTR-2 is
diﬀerentially spliced to form a long (SSTR2A) and a short
(SSTR2B) form [9,10]. Each SSTR binds SST-14 and SST-28*Corresponding author. Fax: +713 798 3649.
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28 with a 10–15 times higher aﬃnity than any other family
members [12,13]. SSTRs also have both cell-subtype and tis-
sue-speciﬁc distribution patterns [14–17]. In the human pan-
creas, it was shown that the predominant receptor on islet
alpha cells is SSTR2, SSTR1 and SSTR5 are expressed on
majority of beta cells and SSTR5 is the only receptor expressed
on delta cells [16,18]. Studies by Zambre et al. [19] have shown
that SST-14, SST-28 and SSTR5-speciﬁc analogs inhibited the
glucose-stimulated insulin release in in vitro cultured human
islets. Results from our laboratory using mouse islets in a sim-
ilar study also suggested that SSTR5 plays a pivotal role in
regulating insulin secretion in the mouse pancreas [20].
The generation and phenotype of the global SSTR5 knock-
out (SSTR5/) mouse model have previously been reported
[21–23]. Using the in situ isolated perfused mouse pancreas
model, it was shown that at three months of age, glucose-
stimulated insulin secretion in the global SSTR5/ mouse
model was comparable with that of WT control mice. How-
ever, at 1 year of age, the SSTR5/ mice had signiﬁcantly en-
hanced levels of glucose-stimulated insulin release in vitro.
These in vitro studies suggest that SSTR5 is an inhibitory reg-
ulator of insulin secretion in the mouse pancreas at an older
age [22]. The study by Strowski et al. [23] also supports the
hypothesis that SSTR5 plays an important role in insulin
secretion and glucose metabolism in older mice.
Creation of a global knockout (the mutation is expressed in
all cell types throughout the body) is limited in its speciﬁcity
and in its time course. The alternative method in studying a
speciﬁc gene function in animal models is to generate a
cell- or tissue-speciﬁc knockout. This allows the speciﬁc target-
ing of a mutation and allows some control in terms of the time
and the speciﬁc cell type that the mutation will be expressed.
Several diﬀerent methods, including the FLP/FRT and Cre/
loxP system, have been successful [24–28]. A very well deﬁned
method to accomplish cell type or tissue type restricted gene
knockout is the Cre/lox system [29]. Cre recombinase has been
isolated from both yeast and phage and reported to excise the
ﬂoxed gene eﬃciently [24,25,30–34]. The 38-kDa protein func-
tions as a site-speciﬁc recombinase and excise the DNA se-
quence ﬂanked between the two speciﬁc 34-bp sequences,
known as loxP [35–38]. The Cre-loxP system can be used to
inactive virtually any gene in any tissue in a developmentally
regulated manner. It holds a tremendous potential to deter-
mine the role of a protein in a particular tissue and to analyze
the pathophysiological consequences of this genetic alteration
in mice. The important features of this systems are that the
target gene can be inactivated at a certain stage duringblished by Elsevier B.V. All rights reserved.
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any desired time.
The Cre recombinase system has been used in many animal
model studies [39–41]. One example is the transgenic mouse
model carrying the rat insulin promoter coupled with Cre
recombinase (RIP-Cre) used in the study of PDX-1 regulated
pancreatic islet cell diﬀerentiation and insulin secretion. The
expression levels of the transgene from various organs have
been studied and results showed that the expression of Cre
recombinase was speciﬁcally located in the islet beta cells
two months after birth and the gene expression eﬃciency
was 85% at three months of age [42,43].
The purpose of this study was to examine insulin secretion
and glucose homeostasis in a mouse model in which the
SSTR5 was speciﬁcally deﬁcient on beta cells by three months
of age using the Cre/loxP system. Morphologic alterations in
the bSSTR5Kd pancreas were examined using immunohisto-
chemical methods. In vivo and in vitro glucose-stimulated
insulin secretion were investigated using glucose and insulin
tolerance tests as well as islet culture techniques.2. Materials and methods
2.1. Antibodies
Antibodies against insulin, glucagon, and somatostatin were ob-
tained from Vector Laboratories Inc. (Burlingame, CA). Polyclonal
antibody against SSTR1 was purchased from Novus Biological Inc.
(Newington, NH). The polypeptide assembling the mouse SSTR5 c-
terminal protein sequence, KSGRPQTTLPTRSC, was synthesized in
the Biochemistry Core Laboratory at Baylor College of Medicine.
Rabbit polyclonal antibody against the SSTR5 c-terminal peptide
was generated by Bethyl Laboratories, Inc. (Montgomery, TX). Fluo-
rescein isothiocyanate (FITC) conjugated anti-rabbit IgG and Cy-3
conjugated anti-Goat IgG antibodies were purchased from Sigma
(St. Louis, MO).
2.2. Generations of the targeting construct and chimera mouse
The mouse SSTR5 gene was cloned and its sequences were
published earlier [22,44]. To generate beta-cell speciﬁc SSTR5
knockdown mice, two strands of the 34 nucleotides long loxP
sequence, 5 0ATAACTTCGTATAGCATACATTATACGAAGTTA-
T3 0 and 5 0ATAACTTCGTATAATGTATGCTATACGAAGTT-
AT3 0, were synthesized. The loxP sequence was ligated to the BglII
site located at 450 bp upstream of ATG sequence in the mouse
SSTR5 promoter region. A 3.5 kb fragment of the mSSTR5 geno-
mic DNA, including the coding sequence, was subcloned into the
pALTER vector (Promega, Madison, WI). A 4 kb DNA fragment
of the selection markers ﬂanked by loxP sequences was isolated
from pNeo-tk-lox plasmid by digestion with BstxI and ligated into
MluI//XhoI sites. The correct insert was determined through restric-
tion-enzyme digestion and limited-sequence analysis. The targeting
construct has 5.5 and 1 kb of ﬂanking sequences at the 5 0 and 3 0
end, respectively. The targeting construct was linearized with Nhel,
a unique site located in pALTER vector and used for electropora-
tion into the ES cells. Positive selection was carried out the next
day using G418 for 14 days. The surviving ES cells that were then
expanded and microinjected into 3.5-day-old blastocysts of C58BL/6
to develop a mouse model in which the mSSTR5 gene had been
ﬂanked by loxP sequences (fSSTR5). A 0.75 kb internal probe iso-
lated by digesting with BsrgI/BglII restriction enzymes was used
for Southern blot analysis to identify positive clones.
2.3. PCR analysis
To identify the mice carrying all three gene constructs, four sets
of PCR assays were used. Primers for the fSSTR5 gene were
5 0GTCAACCTGGCCTTCACGCTA3 0 and 5 0CGACGGTATCGA-
TAAGCTTG3 0. Primers for the SSTR5 WT were 5 0ACACC-
TAGCTGGAATGCCTCA30 and 50CAGTAGGAGACAGCATTC30,corresponding to the sequence from bp 265 to 546 in the mSSTR5
gene. PCR primers for the pNEO-TK cassette consisted of
5 0AAGGCAGTCTGGAGCAT3 0 and 5 0AACCTGCGTGCAATCC-
ATCTT3 0 corresponding to bp 2281–2806. PCR primers for Cre
recombinase were 5 0GCCTGCATTACCGGTCGAT3 0 and 5 0CAC-
GTTCACCGGCATCAACG3 0. Ampliﬁcation of MgCl2 was carried
out for 5 min at 94 C, followed by 25–30 cycles of 94 C for 1 min,
55 C for 1 min, and 74 C for 1 min, and a ﬁnal extension step at
74 C for 10 min. Ampliﬁcation products were visualized in 1% aga-
rose gel.
2.4. Intraperitoneal glucose and insulin tolerance tests
Following a 16-h fast with free access to water, mice were anesthetized
by an intraperitoneal injection of Avertin (2,2-tribromoethanol). Blood
was obtained using a glass pipette from the retro-orbital venous plexus.
Glucose values were determined using the Glucose Analyzer 2 (Beck-
man-Coulter; Fullerton, CA). The serum insulin values were determined
using a rat insulin RIA kit (Linco Research; St. Charles, MO). Mice
were then allowed to recover for 10–14 days after which time they under-
went another 16-h fast. After the fast, each mouse received an IP (intra-
peritoneal) injection of glucose at a concentration of 1.2 g/kg body
weight for three months old and 2.0 g/kg for older mice. At diﬀerent
time points following the injection, mice were anesthetized and blood
samples were collected to determine glucose and insulin values using
the method described above. In another setting, a group of mice were
given an IP injection of human insulin solution (Eli Lilly, Indianapolis,
IN) at a concentration of 10 mU/kg body weight. Blood samples were
collected at 5, 10, 15, 30, 60 and 90 min. Six to eight mice were used
for each time point and sacriﬁced at the end of the experiment.
2.5. In vitro islet isolation and culture
Mouse islets were isolated using a modiﬁed collagenase digestion
solution as reported earlier [20]. Isolated islets were placed into a 24
well culture dish with islets per well and 1 ml of RPMI without glucose
and 10% fetal bovine serum (FBS). Islets were incubated at 37 C in a
95% O2/5% CO2 incubator for 3 h to recover and then transferred into
RPMI/10% FBS with 3.9 mM glucose and incubated for 1.5 h. Islets
were then transferred into RPMI medium containing 10% FBS with
3.9 and 16.7 mM glucose with or without SST peptides and incubated
for 1 h. Culture medium was collected for subsequent determination of
insulin and glucose levels as described previously.
2.6. Immunohistochemistry analysis
Pancreata were ﬁxed in 10% formalin for 24 h and embedded in par-
aﬃn. Tissue sections were cut and slides were deparaﬃnized in xylene.
The sections were hydrated through graded alcohol and slides were
prepared and placed in a humidiﬁed chamber overlaid with diluted
antibodies against insulin, glucagon or somatostatin (Vector Labora-
tories) overnight at 4 C. The dilution factors for insulin, glucagon,
and SST were 75, 200, and 75, respectively. After washing with PBS,
tissue sections were incubated with secondary antibodies for 1 h at
room temperature. Color was then developed with DAB substrate
solutions recommended by the manufacturer (Vector Laboratories).
For SSTR5 and SSTR1 immunostaining, pancreata were ﬁxed in 4%
paraformaldehyde for 4 h at 4 C. Tissue samples were embedded in
paraﬃn as described above. The dilution factors for SSTR5 and
SSTR1 were 100 and 50, respectively, and the incubation was carried
out overnight at 4 C. Slides were washed three times with PBS con-
taining 5% non-fat milk and 1% horse serum. FITC conjugated anti-
rabbit IgG and Cy3 conjugated anti-goat IgG antibodies (diluted 1/
200) were then applied and the incubation was carried out for 1 h at
room temperature. The tissue sections were washed and cover slides
were applied. Simultaneous ﬂuorescence-microscope observation and
photography were carried out at the microscopic core facility at Baylor
College of Medicine using an Anxioplan microscope and MetaVeu
software. The percentage of immunopositive cells and the intensities
of each staining were analyzed using SimplePCI software (Compix,
Inc., Tualatin, OR).
2.7. Data presentation and statistical analysis
Insulin and C-peptide levels were determined in duplicates in all
cases using RIA kits from Linco Research (St. Louis, MO). Insulin
data are presented as means ± S.E.M. in ng/ml. C-peptide levels are
presented as means ± S.E.M. pM. Serum glucose levels were measured
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sented as means ± S.E.M. in mg/dL. Each group consisted of six to
eight mice matched by age and sex. Unpaired students t test was used
for statistical analysis with P < 0.05 indicating signiﬁcance.3. Results
3.1. Generating the chimeric mouse
The targeting construct of SSTR5-lox gene is shown in Fig.
1A. Homozygous fSSTR5 mice are indistinguishable from WT
littermate controls in all aspects. RIP-Cre mice were gener-
ously donated by Dr. Edlund (University of Umea, Sweden)
and crossbred with global SSTR5/ mice to generate RIP-
Cre/SSTR5/ mice. These oﬀspring mice were then crossbred
with fSSTR5 mice to generate a mouse model that carried one
allele of deleted SSTR5 mutant and one allele of fSSTR5. This
breeding strategy was designed based on the concerns that: (a)
RIP-Cre heterozygous may not be suﬃcient to delete both
fSSTR5 alleles in vivo and (b) that global SSTR5+/ mice have
demonstrated no phenotypic diﬀerences compared to WT con-
trol mice at young age [22,23]. Four separate PCR analyses
were used to identify mice that were positive for the loxP
sequence, the RIP-Cre construct and the SSTR5+/ gene
(Fig. 1B). Beta cell-speciﬁc SSTR5 gene-knockdown mice
(bSSTR5Kd) were viable and fertile with no signiﬁcant behav-
ior alterations compared to WT littermate controls.
To demonstrate the ablation of SSTR5 in the mouse pan-
creas, pancreata were removed from male and female
bSSTR5Kd mice and stained with rabbit anti-SSTR5 poly-
clonal antibodies. As shown in Fig. 1C, positive staining for
SSTR5 was observed in both female and male WT mice at
three months of age (A and B, respectively). Mice carryingFig. 1. Generating beta cell-speciﬁc bSSTR5Kd mice. (A) A schematic pres
product of RIP-Cre/loxP recombination. The PCR primers used for genotyp
events are shown (arrows). The 0.75 kb internal probe used in the Southern b
mouse tail DNA using PCR method. (C). SSTR5 expression in the mouse pa
male WT mouse islet. (c) 1-month-old female bSSTR5Kd mouse islet. (d
bSSTR5Kd mouse islet. (f) 3-month-old male bSSTR5Kd mouse islet. Magniall three gene constructs, fSSTR5, RIP-Cre, and a null allele
of the SSTR5 gene, demonstrated a signiﬁcant decrease of
SSTR5 expression as early as four weeks of age (C, female;
D, male), suggesting that the RIP-Cre transgene was being ex-
pressed at that time. At three months of age, pancreata from
male and female bSSTR5Kd mice had no staining of SSTR5
in beta cells, suggesting that gene ablation was complete. Duc-
tal cells in the same mouse pancreas stained positive for
SSTR5, indicating that the gene ablation only occurred in beta
cells (F).3.2. Impaired glucose-stimulated insulin secretion in bSSTR5Kd
mice
To investigate in vitro inhibition of insulin secretion by SST
peptides, islets isolated from bSSTR5Kd and WT mice at three
months of age were placed into a 24-well culture dish with
three islets per well. Islets were washed and transferred into
RPMI medium containing 10% FBS and either 3.9 mM (low,
Fig. 2A) or 16.7 mM (high, Fig. 2B) glucose in combination
with SST peptides at the same concentration of 40 nM. As
shown in Fig. 2A, one-hour post treatment in low glucose solu-
tion, there was no diﬀerence in basal insulin levels released by
bSSTR5Kd and WT control mouse islets. When WT mouse is-
lets incubated with octreotide in low glucose, results showed a
decrease of insulin secretion. However, the same levels of SST-
14 and SST-28 had no signiﬁcant eﬀect on WT islets. Whereas
bSSTR5Kd mouse islet had signiﬁcantly reduced levels of insu-
lin release when incubated with SST-14, SST-28, or octreotide.
In addition, when incubated with high glucose solution,
bSSTR5Kd mice had signiﬁcantly reduced levels of glucose-
stimulated insulin secretion compared to that seen in WT con-
trols (Fig. 2B). Glucose-stimulated insulin secretion in WTentation of the targeting construct, genomic DNA, and the expected
ing and the probes used for conﬁrmation of correction recombination
lot analysis is also indicated (black bar). (B) Genotyping of bSSTR5Kd
ncreatic islet. (a) 3-month-old female WT mouse islet. (b) 3-month-old
) 1-month-old male bSSTR5Kd mouse islet. (e) 3-month-old female
ﬁcation 300·.
Fig. 2. Diminished response to SST peptide treatment in vitro. Islets
were isolated from three male and three female bSSTR5Kd mice at
three months of age. Age and sex matched WT mice were used as
controls. Hand-picked islets were transferred into 24-well cell culture
plate at three islets per well. After wash, islets were incubated with low
glucose (A, 3.9 mM) or high glucose (B, 16.7 mM) solutions and
treated with somatostatin peptides at the same concentration of
40 nM. Insulin levels were determined as described before and
presented as means ± S.E.M., \P < 0.05. (A) Islet culture with low
glucose levels (3.9 mM). (B) Islet culture with high glucose levels
(16.7 mM).
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octreotide were added to the medium (P < 0.05 for all three
treatments). On the other hand, octreotide signiﬁcantly sup-
pressed glucose-stimulated insulin secretion in bSSTR5Kd
mouse islets (P < 0.05), whereas the inhibition of insulin secre-
tion by SST-14 was not signiﬁcant (P < 0.07). Furthermore,
the glucose-stimulated insulin secretion from bSSTR5Kd mice
was not signiﬁcantly aﬀected by incubation with SST-28.
3.3. Glucose intolerance in vivo
To investigate glucose homeostasis in bSSTR5Kd mice at
three months of age, blood samples were obtained from
bSSTR5Kd mice and the sex- and age-matched WT mice. As
shown in Fig. 3, both fasting glucose and serum insulin levels
of bSSTR5Kd mice were similar to that of WT mice. Intraperi-
toneal glucose tolerance tests (IPGTT) were then carried out in
both WT and bSSTR5Kd mice. Both glucose (3A) and insulin
(3B) levels in WT mice were signiﬁcantly increased at 15 min
post injection. bSSTR5Kd mice also had similarly elevated lev-
els of blood glucose levels 15 min post injection, however,
serum insulin levels in the bSSTR5Kd mice were unchanged.
Glucose tolerance tests were also performed in 12 months
old mice. As shown in Fig. 3C, bSSTR5Kd mice had signiﬁ-
cantly reduced fasting glucose levels compared with that of
age and sex-matched WT controls. The basal insulin levels in
bSSTR5Kd mice were signiﬁcantly higher than that of WT con-
trols (3D). After the glucose injection, bSSTR5Kd mice alsohad much higher increase of serum glucose levels compared
with that of WT mice (P < 0.05 at each time point). At the
same time points after glucose stimulation, serum insulin levels
in bSSTR5Kd mice were at 2.9 ± 0.25, 5.1 ± 0.45, 4.0 ± 0.0.45,
3.7 ± 0.31 and 3.7 ± 0.32 ng/ml (5D). Whereas the serum insu-
lin levels in WT mice were 2.4 ± 0.06, 4.3 ± 0.07, 3.3 ± 0.20,
2.8 ± 0.1 and 3.2 ± 0.25 ng/ml (P < 0.05 T0, 15 and 60 min
post injection).
3.4. Sustained increase of C-peptide levels and faster insulin
clearance in bSSTR5Kd mice
Serum C-peptide levels in bSSTR5Kd mice at 3 and 12
months of age were compared with that of age matched WT
controls. bSSTR5Kd mice had 196 ± 9.5 and 217 ± 7.5 pM of
serum C-peptide at 3 and 12 months of age, whereas in the
age matched WT mice the serum C-peptide levels were
166 ± 4.0 and 194 ± 2.1 pM (P < 0.05 for each time point).
These data suggest that bSSTR5Kd mice had increased levels
of insulin release from beta cells at all ages.
Insulin tolerance tests were then carried out in 3 months old
bSSTR5Kd mice and compared with that of age-matched WT
controls. As shown in Fig. 4A, after an IP injection of insulin
solution at a dose of 10 mU/kg of body weight, the systemic
glucose levels in WT mice were signiﬁcantly reduced. The glu-
cose levels in bSSTR5Kd mice also decreased during the course
of insulin stimulation. However, serum glucose levels in
bSSTR5Kd mice returned to normal level earlier than that of
WT controls (P < 0.05 at 60 min compared to that of WT).
In addition, system insulin levels in bSSTR5Kd mice were also
cleared much faster that that in WT controls (P < 0.05 at 15,
30, and 60 min post injection, Fig. 4B). These data demonstrate
a signiﬁcant increase of insulin clearance in bSSTR5Kd mice.3.5. Alterations in somatostatin and SSTR1 expressions in the
bSSTR5Kd mouse pancreas
To investigate the endocrine hormone production in SSTR5
gene deﬁcient mice, pancreas sections were stained with anti-
bodies against insulin, glucagon, and SST. The immunostain-
ing results of the male mouse pancreas are shown in Fig. 5A,
with female mouse islet in panel A and male mouse islet in pa-
nel B. Compared to that of WT mice (C for both panels),
bSSTR5Kd mice demonstrated a signiﬁcant decrease of SST
immunopositive cells (F for both panels). Quantitative analysis
of the islets from both strains of mice showed that 80% of the
islet cells are insulin-producing beta cells, whereas 13% and 9%
of islet cells in WT mice are somatostatin-producing delta cells
(female and male mice, respectively). The number of SST
immunopositive delta cells was signiﬁcantly reduced to 7%
and 3% in bSSTR5Kd mouse islets (female and male mice,
respectively, P < 0.05 for both sexes).
Somatostatin receptor subtype 1 has been found in 100% of
beta cells and its internalization was believed to require the
presence of SSTR5 [18,45]. We then performed an immunohis-
tochemistry analysis to investigate the possibility that SSTR1
may compensate the loss of SSTR5 in the beta cells. As shown
in Fig. 6, immunohistochemical analysis revealed a signiﬁcant
increase of SSTR1 immunostaining in three months old
bSSTR5Kd mouse islet (6C) compared to that of age-matched
WT controls (6A). Quantitative analysis indicated that the
SSTR1-positive cells were signiﬁcantly increased from 50.3%
of insulin producing cells in WT mice to 89.6% of insulin
Fig. 3. Glucose intolerance in bSSTR5Kd mice at 3 and 12 months of age. Mice were fasted overnight with free access of water. Mice were
anesthetized with an IP injection of Avertine solution. Blood sample was drawn using a glass peptide through the orbital vein. Mice were allowed to
recover for 10–14 days before another fast was taken place. After 12–16 h starvation, mice were given an IP injection of glucose solution at the
concentration of 1.2–2.0 g/kg of body weight. Blood samples were collected at 15, 30, 60, 90 or 120 min. Serum was used for glucose and insulin
determinations. Six to eight mice were used for each time point and mice were only used once. (A) Glucose levels at three months of age. (B) Insulin
levels at three months of age. (C) Glucose levels at 12 months of age. (D) insulin levels at 12 months of age. Data are presented as means ± S.E.M.
and P < 0.05 indicate signiﬁcant.
Fig. 4. Increase of insulin clearance in bSSTR5Kd mice at three
months of age. After an overnight fast, mice at three months of age
were given an IP injection of human insulin solution at the dose of
10 mU/kg of body weight. Blood samples were collected at 5, 10, 15,
30, 60 and 90 min. Six to eight mice (both sexes) were used for each
time point and mice were only bled once. Serum glucose (A) and
insulin (B) levels were determined as before. Both glucose and insulin
levels are presented as means ± S.E.M., \P < 0.05.
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data suggest that SSTR1 may compensate for the loss of
SSTR5 and play an important role in regulating insulin secre-
tion in bSSTR5Kd mice at three months of age, the time when
gene ablation occurs. However, at 12 months of age, SSTR1
expression was signiﬁcantly reduced both in WT and
bSSTR5Kd mouse islets (B and D for WT and bSSTR5Kd mice,
respectively).4. Discussion
In the present study, the SSTR5 gene was knocked down
from beta cells in mice at three months of age. In vitro islet cul-
ture analyses have shown that while SST-28 has no eﬀect on
glucose-stimulated insulin secretion in bSSTR5Kd mouse islet,
both SST-14 and octreotide treatment resulted in a signiﬁcant
reduction of insulin release. Because SST-28 has 10–15 times
more speciﬁcity towards SSTR5 than any other SSTR family
members, this result is consistent with the absence of SSTR5.
These data also suggest that other SSTRs are present in the is-
let and may regulate SST-14/octreotide mediated inhibition of
glucose-stimulated insulin release. In addition, both SSTR1
and SSTR5 have been found in the majority of beta cells. It
is possible that these receptors have redundant functions and
be able to compensate when a family member was diminished.
SSTR1 immunopositive cells were signiﬁcantly increased in
bSSTR5Kd mouse islets at three months of age, suggesting that
expression of SSTR1 was enhanced at the time of SSTR5 gene
ablation. The overexpressed SSTR1 hence may compensate the
loss of SSTR5 and temporally modulate insulin secretion in
vivo. Like many other developmental related genes, SSTR1
expression was reduced in the islets of both bSSTR5Kd mice
Fig. 5. Decreased levels of somatostatin expression in bSSTR5Kd
mouse islets. A series of tissue sections are prepared and incubated
with anti-insulin, glucagons and somatostatin antibodies at 4 C
overnight. Tissue sections were then incubated with secondary
antibodies and color was developed with DAB substrate solutions.
Photographs were captured by light microscopy and analyzed as
described. Magniﬁcation 300·. (A) Immunostaining of female WT
(upper panel) and female bSSTR5Kd mouse islets (lower panel). (B)
Immunostaining of male WT (upper panel) and male bSSTR5Kd
(lower panel) mouse islets. (C) Quantitative analysis of somatostatin
immunopositive cells in the islet. Bar plot represents the percentage of
SST immunopositive cells in the mouse islets. Three male and three
female mice of both bSSTR5Kd and WT strains were analyzed.
Experimental procedures were repeated three times and 5–6 islets were
analyzed from each section.
Fig. 6. Changes of SSTR1 expression in the bSSTR5Kd mouse islets.
Expressions of SSTR1 in three months old WT mouse islet (A), 12-
months old male WT mouse islet (B), three months old bSSTR5Kd
mouse islet (C), and 12 months old bSSTR5Kd mouse islet (D) are
shown. Three male and three female mice of both bSSTR5Kd and WT
strains were analyzed. Experimental procedures were repeated three
times and 6–10 individual islets were analyzed from each section.
Magniﬁcation 300·.
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loss of SSTR1 in bSSTR5Kd mice resulted in a loss of compen-
sation by SSTR1 seen in younger mice, thus leading to hypo-
glycemia and hyperinsulinemia in older mice. These age
related abnormal insulin levels have also been found in global
SSTR5/mice earlier [22,23]. In our study of SSTR1/5 double
knockout mice, global gene ablation of both SSTR1 and 5 re-
sulted in a sustained increase of insulin release and an exagger-
ated insulin secretion pattern after glucose stimulation at six
months of age [46]. These data further suggest that the regula-
tion of insulin secretion by SSTR1 and 5 is associated with age
and that SSTR5 is the predominant inhibitory regulator of
insulin in older mice.Although bSSTR5Kd mice appear phenotypically normal
up to three months of age, glucose tolerance tests suggest
that both male and female bSSTR5Kd mice were glucose
intolerant. The serum insulin levels in response to glucose
stimulation were essentially absent in bSSTR5Kd mice. These
results are diﬀerent from those seen in global homozygous
SSTR5 knockout mice, which had comparable basal glucose
and insulin levels at three months of age compared to WT
controls. On the other hand, insulin clearance was signiﬁ-
cantly enhanced in the bSSTR5Kd mice compared to that
of WT mice at the same age. These data therefore suggest
that the unchanged systemic insulin levels may not directly
reﬂect the ability of insulin production and secretion in re-
sponse to glucose stimulation in vivo. In addition, the
IPGTT analysis at 12 months of age indicated that
bSSTR5Kd mice are hypoglycemic and hyperinsulinemic,
suggesting that SSTR5 is the predominant inhibitory regula-
tor of insulin secretion in older mice. The increase of C-pep-
tide levels and the higher rate of insulin clearance suggest a
sustained insulin release due to the membrane protein dele-
tion. The analysis of basal levels of serum glucose, insulin
and C-peptide in these mice at diﬀerent ages further indi-
cates that the cause of serum glucose decrease at an older
age in the bSSTR5Kd mice was associated with the consis-
tent increase of insulin secretion. Because SSTR5 regulates
Ca2+ gated channels and modulates insulin secretion, it is
possible that gene ablation in islet cells results in a leaky
system so that insulin could be released without changing
the potentiation of the membrane. These results implicate
that the alterations of insulin release in bSSTR5Kd mice lead
to alterations in glucose homeostasis in these mice.
In summary, this study reports the development of a mouse
model in which the SSTR5 gene was knocked down speciﬁcally
X.P. Wang et al. / FEBS Letters 579 (2005) 3107–3114 3113in islet beta cells using the Cre/loxP system. These mice demon-
strated a distinct phenotype with growth retardation, glucose
intolerance at young age, reduced insulin response to glucose,
increased insulin clearance at three months of age, and subse-
quent normalization of growth, hypoglycemia and hyperinsu-
linemia at 12 months of age. Decreased levels of SS-
immunopositive cells were found in bSSTR5Kd mouse islets,
which correlated with the diminished response of SST medi-
ated inhibition of insulin secretion in vitro. At the time of
SSTR5 gene knockdown at three months of age, SSTR1
expression was signiﬁcantly enhanced, however SSTR1 expres-
sion was reduced by 12 months of age, at which time the
bSSTR5Kd mice had hypoglycemia and hyperinsulinemia. This
mouse model is thus a useful tool for the study of intraislet
cell–cell communication, SSTR5/SSTR1 interaction and int-
raislet regulation of insulin secretion and glucose homeostasis
in mice.
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